Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
- Status
- AVAILABLE
- Phase
- N/A
Clinical Trials Related to Sevabertinib
Related studies linked through entity extraction aliases.
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Status
- RECRUITING
- Phase
- PHASE3